Clindamycin phosphate
Clindamycin phosphate: 15 brands, 74 generics; first approved Feb 08, 1982; generic available.
Generic available: 74 ANDA applications approved.
Brand (NDA) products
- ORGANON LLCNDA 2156502021
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 2% BASE GEL VAGINAL Rx - - BAXTER HLTHCARE CORPNDA 20808320173 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 300MG BASE/50ML (EQ 6MG BASE/ML) SOLUTION INTRAVENOUS Rx - EQ 600MG BASE/50ML (EQ 12MG BASE/ML) SOLUTION INTRAVENOUS Rx - EQ 900MG BASE/50ML (EQ 18MG BASE/ML) SOLUTION INTRAVENOUS Rx - - PADAGIS USNDA 0507932004
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 2% BASE CREAM VAGINAL Rx - - EVOCLINRLDQUAGENNDA 0508012004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% AEROSOL, FOAM TOPICAL Discontinued - - BAUSCHNDA 0507822000
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB2 - PFIZERNDA 0507671999
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG SUPPOSITORY VAGINAL Rx - - CLEOCINRLDPFIZERNDA 05068019982 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 2% BASE CREAM VAGINAL Discontinued - EQ 2% BASE CREAM VAGINAL Rx AB - ABRAXIS PHARMNDA 0506351989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 900MG BASE/100ML INJECTABLE INJECTION Rx - - PFIZERNDA 05063919893 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Discontinued - EQ 12MG BASE/ML INJECTABLE INJECTION Discontinued - EQ 18MG BASE/ML INJECTABLE INJECTION Discontinued - - PFIZERNDA 0506001989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE LOTION TOPICAL Rx AB - PFIZERNDA 0506151987
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - PFIZERNDA 050441-
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Rx AP - CLEOCIN TRLDPFIZERNDA 050537-2 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - EQ 1% BASE SWAB TOPICAL Discontinued - - BAXTER HLTHCARENDA 05064819893 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Discontinued - EQ 12MG BASE/ML INJECTABLE INJECTION Discontinued - EQ 900MG BASE/100ML INJECTABLE INJECTION Discontinued - - ABRAXIS PHARMNDA 0506361989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12MG BASE/ML INJECTABLE INJECTION Discontinued -
Generic (ANDA) products (74)
- CLINDAMYCIN PHOSPHATERISINGANDA 2183002026
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SWAB TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEAUROBINDO PHARMA LTDANDA 2189422026
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATECARNEGIEANDA 2196122025
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SWAB TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEALEMBICANDA 2124662024
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATEZYDUS LIFESCIENCESANDA 2165872023
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - HIKMAANDA 21440120233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Rx AP EQ 12MG BASE/ML INJECTABLE INJECTION Rx AP EQ 18MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATEAMNEALANDA 2152192022
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEAMNEALANDA 2146682022
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB2 - CLINDAMYCIN PHOSPHATEENCUBEANDA 2156072022
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE LOTION TOPICAL Rx AB - CLINDAMYCIN PHOSPHATEGLENMARK PHARMS LTDANDA 2107782021
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% AEROSOL, FOAM TOPICAL Rx AT - CLINDAMYCIN PHOSPHATESOLARIS PHARMA CORPANDA 2128422021
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB2 - CLINDAMYCIN PHOSPHATESUN PHARMA CANADAANDA 2145262021
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE LOTION TOPICAL Rx AB - CLINDAMYCIN PHOSPHATEENCUBEANDA 2124382021
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATEPADAGIS ISRAELANDA 2146042021
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE LOTION TOPICAL Rx AB - CLINDAMYCIN PHOSPHATEGLENMARK PHARMS LTDANDA 2142512021
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATEPADAGIS ISRAELANDA 2121042020
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATESUN PHARMA CANADAANDA 2140522020
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATESOLARIS PHARMA CORPANDA 2118722020
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATETAROANDA 2100042020
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% AEROSOL, FOAM TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEENCUBE ETHICALSANDA 2099142019
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEZYDUS LIFESCIENCESANDA 2087672018
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Rx AT - CLINDAMYCIN PHOSPHATECHARTWELL RXANDA 2098462018
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Rx AT - CLINDAMYCIN PHOSPHATERISINGANDA 2047482017
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATERISINGANDA 2047492017
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - BAXTER HLTHCARE CORPANDA 20808420173 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Rx AP EQ 12MG BASE/ML INJECTABLE INJECTION Rx AP EQ 18MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATEPAI HOLDINGS PHARMANDA 2069452016
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEPH HEALTHANDA 2033432015
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - RISINGANDA 20304820133 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Rx AP EQ 12MG BASE/ML INJECTABLE INJECTION Rx AP EQ 18MG BASE/ML INJECTABLE INJECTION Rx AP - SANDOZ INCANDA 20169220123 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Rx AP EQ 12MG BASE/ML INJECTABLE INJECTION Rx AP EQ 18MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATESAGENT PHARMS INCANDA 0901082011
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATESAGENT PHARMS INCANDA 0901092011
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATEEPIC PHARMA LLCANDA 0655132010
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SWAB TOPICAL Rx AT - CLINDAMYCIN PHOSPHATERSPADAGIS ISRAELANDA 0907852010
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% AEROSOL, FOAM TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEFRESENIUS KABI USAANDA 0653472007
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEFRESENIUS KABI USAANDA 0653462007
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEFOUGERA PHARMSANDA 0652542006
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATERSFOUGERA PHARMSANDA 0651392004
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 2% BASE CREAM VAGINAL Rx AB - CLINDAMYCIN PHOSPHATEHIKMAANDA 0652062004
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATETARO PHARM INDSANDA 0651842004
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEFOUGERA PHARMSANDA 0650672002
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE LOTION TOPICAL Rx AB - ABBOTT LABSANDA 06502720013 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 6MG BASE/ML INJECTABLE INJECTION Discontinued - EQ 12MG BASE/ML INJECTABLE INJECTION Discontinued - EQ 18MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATERSPADAGIS USANDA 0650492000
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SWAB TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEFOUGERA PHARMSANDA 0641602000
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE GEL TOPICAL Rx AB1 - CLINDAMYCIN PHOSPHATEXTTRIUM LABS INCANDA 0633041997
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEFOUGERA PHARMS INCANDA 0641591997
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Rx AT - PERRIGO COANDA 0641361996
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SWAB TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEINGENUS PHARMS LLCANDA 0641081996
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATERSPADAGIS USANDA 0640501995
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Rx AT - CLINDAMYCIN PHOSPHATEBEDFORDANDA 0631631994
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - PADAGIS USANDA 0633291992
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATETEVA PARENTERALANDA 0632821992
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEWATSON LABSANDA 0630791990
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATETEVA PARENTERALANDA 0630411989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEHIKMAANDA 0630681989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEVINTAGE PHARMSANDA 0629301989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEIGI LABS INCANDA 0629281989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEBRISTOL MYERS SQUIBBANDA 0629081989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEBOCA PHARMA LLCANDA 0629441989
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEMARSAM PHARMS LLCANDA 0629131988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEALMAJECTANDA 0629431988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEG AND W LABS INCANDA 0628111988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - CLINDAMYCIN PHOSPHATEWATSON LABSANDA 0629001988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEABRAXIS PHARMANDA 0627471988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATELOCHANDA 0629051988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEHIKMAANDA 0628891988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATEHIKMAANDA 0629531988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATESOLOPAKANDA 0628521988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATESOLOPAKANDA 0628191988
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - PFIZERANDA 0628031987
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Rx AP - CLINDAMYCIN PHOSPHATEHIKMAANDA 0628061987
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEALMAJECTANDA 0628001987
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - CLINDAMYCIN PHOSPHATEALMAJECTANDA 0628011987
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued - - PHARMACIA AND UPJOHNANDA 0623631982
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1% BASE SOLUTION TOPICAL Discontinued - - PHARMACIA AND UPJOHNANDA 061839-
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 150MG BASE/ML INJECTABLE INJECTION Discontinued -
Patent & exclusivity timeline
Marketing exclusivity
- NPNew product exclusivity (3 years)
1 yr 11 mo ago
- GAINQualified infectious disease product exclusivity (adds 5 years)
in 3 yr 2 mo
Listed patents
| Patent | Expires | In | Type |
|---|---|---|---|
| 9789057 | in 1 mo | ProductU-137 | |
| 11129896 | in 10 yr 1 mo | U-3293 | |
| 12303563 | in 10 yr 1 mo | Product |
Approval history
Approvals span 1982โ2026 across 89 FDA applications.
Clindamycin phosphate: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Clindamycin phosphate
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo
